Lb Pharmaceuticals Inc (LBRX)

$32.02 +0.89 (2.86%)
Market Cap 937.56M
Revenue (ttm) 0.00
Net Income (ttm) -25.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 90,926
Avg Vol 254,772
Day's Range N/A - N/A
Shares Out 28.68M
Stochastic %K 22%
Beta N/A
Analysts Strong Sell
Price Target $44.00

Company Profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 605 0300
Website: lbpharma.us
Address:
One Pennsylvania Plaza, Suite 1025, New York, United States
Latest News on LBRX
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)

2026-05-12T21:46:31.000Z - 21 hours ago

LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:05 PM EDT - 22 hours ago

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals initiated with a Buy at H.C. Wainwright

2026-04-27T10:17:17.000Z - 16 days ago

LB Pharmaceuticals initiated with a Buy at H.C. Wainwright

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

Apr 22, 2026, 4:05 PM EDT - 20 days ago

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

LB Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 11:45 AM EDT - 27 days ago

LB Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy

2026-04-10T13:16:25.000Z - 4 weeks ago

Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy

LB Pharmaceuticals initiated with a Buy at Craig-Hallum

2026-04-10T11:33:55.000Z - 4 weeks ago

LB Pharmaceuticals initiated with a Buy at Craig-Hallum

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 4:05 PM EDT - 4 weeks ago

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

LB Pharmaceuticals files to sell 4.78M shares of common stock for holders

2026-04-06T20:13:02.000Z - 5 weeks ago

LB Pharmaceuticals files to sell 4.78M shares of common stock for holders

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

Mar 27, 2026, 12:00 PM EDT - 6 weeks ago

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals price target raised to $40 from $35 at Stifel

2026-03-27T10:20:11.000Z - 6 weeks ago

LB Pharmaceuticals price target raised to $40 from $35 at Stifel

LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)

2026-03-26T20:12:07.000Z - 6 weeks ago

LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 26, 2026, 4:05 PM EDT - 6 weeks ago

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LB Pharmaceuticals initiates NOVA-2 trial

2026-03-25T12:26:54.000Z - 7 weeks ago

LB Pharmaceuticals initiates NOVA-2 trial

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

Mar 25, 2026, 8:00 AM EDT - 7 weeks ago

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 2:30 PM EDT - 2 months ago

LB Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

LB Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 1:40 PM EDT - 2 months ago

LB Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

LB Pharmaceuticals appoints Lenz to Board of Directors

2026-03-09T12:27:49.000Z - 2 months ago

LB Pharmaceuticals appoints Lenz to Board of Directors

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

Mar 9, 2026, 8:00 AM EDT - 2 months ago

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

LB Pharmaceuticals to Participate in Upcoming March Investor Events

Mar 4, 2026, 4:05 PM EST - 2 months ago

LB Pharmaceuticals to Participate in Upcoming March Investor Events

LB Pharmaceuticals management to meet with Piper Sandler

2026-02-19T15:46:34.000Z - 2 months ago

LB Pharmaceuticals management to meet with Piper Sandler

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Feb 10, 2026, 4:41 PM EST - 3 months ago

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals prices 3.31M shares at $21.17 in private placement

2026-02-05T13:15:12.000Z - 3 months ago

LB Pharmaceuticals prices 3.31M shares at $21.17 in private placement

LB Pharmaceuticals Announces $100.0 Million Private Placement

Feb 5, 2026, 8:00 AM EST - 3 months ago

LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals initiates Phase 2 trial of LB-102

2026-01-26T13:06:11.000Z - 3 months ago

LB Pharmaceuticals initiates Phase 2 trial of LB-102

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Jan 26, 2026, 8:00 AM EST - 3 months ago

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

LB Pharmaceuticals appoints Pazdera as General Counsel

2026-01-21T13:05:29.000Z - 4 months ago

LB Pharmaceuticals appoints Pazdera as General Counsel

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

Jan 21, 2026, 8:00 AM EST - 4 months ago

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

LB Pharmaceuticals initiated with a Buy at Roth Capital

2026-01-09T09:30:20.000Z - 4 months ago

LB Pharmaceuticals initiated with a Buy at Roth Capital

LB Pharmaceuticals appoints Ellen Rose as SVP, corporate affairs

2026-01-06T12:11:23.000Z - 4 months ago

LB Pharmaceuticals appoints Ellen Rose as SVP, corporate affairs

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

Jan 6, 2026, 7:00 AM EST - 4 months ago

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

LB Pharmaceuticals management to meet with Piper Sandler

2025-12-16T15:40:44.000Z - 5 months ago

LB Pharmaceuticals management to meet with Piper Sandler

LB Pharmaceuticals price target raised to $35 from $27 at Stifel

2025-12-11T12:25:50.000Z - 5 months ago

LB Pharmaceuticals price target raised to $35 from $27 at Stifel

LB Pharmaceuticals added to Russell 2000, Russell 3000 indices

2025-12-09T13:16:01.000Z - 5 months ago

LB Pharmaceuticals added to Russell 2000, Russell 3000 indices

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

Dec 9, 2025, 8:00 AM EST - 5 months ago

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

LB Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:30 AM EST - 5 months ago

LB Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 6 months ago

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

LB Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 9:20 AM EST - 6 months ago

LB Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

2025-11-12T13:15:37.000Z - 6 months ago

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO

NMRA

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

Nov 12, 2025, 8:00 AM EST - 6 months ago

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 6 months ago

LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

Nov 6, 2025, 8:00 AM EST - 6 months ago

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs

Oct 14, 2025, 8:30 AM EDT - 7 months ago

LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

Oct 6, 2025, 8:30 AM EDT - 7 months ago

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

Sep 25, 2025, 8:30 AM EDT - 8 months ago

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

LB Pharma valued at $382 million as shares jump in New York debut

Sep 11, 2025, 12:31 PM EDT - 8 months ago

LB Pharma valued at $382 million as shares jump in New York debut

LB Pharmaceuticals raises $285 million in US IPO

Sep 10, 2025, 9:22 PM EDT - 8 months ago

LB Pharmaceuticals raises $285 million in US IPO

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

Sep 10, 2025, 9:03 PM EDT - 8 months ago

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

Sep 8, 2025, 10:41 AM EDT - 8 months ago

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought